CD8A and neoplasm: Our finding that mTOR inhibition leads to a CD8 cell dependent anti-tumor response in RAS-mutant, immunogenic MOC1 tumors is novel and suggests that mTOR targeting therapies may be useful in multiple tumor types regardless of underlying driver mutations.